Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: blake roberts who wrote (2909)	2/4/1999 9:35:00 AM
From: JustMy2Cents	Read Replies (1) \| Respond to of 4650

Opened at .17

To: blake roberts who wrote (2909)	2/4/1999 10:04:00 AM
From: Bram12345	Read Replies (1) \| Respond to of 4650

Here is the last PR on BioMOda. The company is expecting to market the test kit by the end of the first qtr. Well, March will end the first quarter, so maybe the news will be on the fact that they have begun marketing it. --------------------------------------------------------------------- Advanced Optics Electronics Inc. Announces: BioModa Inc. ''Human Clinical Testing Shows Value of New Diagnostic for Early Detection of Lung Cancer'' BusinessWire, Monday, November 16, 1998 at 08:47 ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Nov. 16, 1998--BioModa Inc. Monday announced the successful completion of the first commercial clinical testing of its TCPP lung cancer diagnostic. An independent, commercial lung cytology laboratory performed the tests. The blinded study has proven that BioModa's technology is now ready to move into the commercialization phase. The company expects to have its test kit in the marketplace by the end of the first quarter of 1999. "This is the validation we've been waiting for. Now it's full speed ahead with the kit," stated Ari Ma'ayan, BioModa's president. BioModa had hoped that the testing would validate the company's conclusion from earlier laboratory work that the technology would be capable of detecting early stages of pre-cancerous conditions of the lung. "The trials have done exactly that," said BioModa's Chief Technical Officer, Jeff Garwin, M.D., Ph.D. "The key to raising the survival rate for any type of cancer is early detection, and up until now there was no test which could accurately, quickly and inexpensively detect patterns of abnormal cells in the lung which could develop into lung cancer. This test should detect those patterns several years before any other diagnostic modality," stated Dr. Garwin. Early detection could raise the 5-year survival rate of lung cancer from 15 percent to 46 percent, and new preventive treatments may be able to halt the progression to lung cancer, if pre-cancerous conditions are detected early enough. Lung cancer strikes nearly 200,000 Americans each year and is the leading cause of cancer death in the United States and the world. BioModa's core technology was developed at Los Alamos National Laboratory and St. Mary's Medical Center in Grand Junction, Colo. BioModa received an exclusive worldwide license to the technology in 1995. The technology is protected by patents, which have issued in the United States and several foreign countries and which are pending in several more. Additionally, the company will file a number of important new patents in the near future. BioModa now intends to start developing products to image and treat lung cancer, based on its exclusive core technology. The company also plans to extend its technology to develop diagnostic tests and treatments for other cancers. Plans call for entering into partnerships with U.S.- and foreign-based corporations for R&D, production, marketing and distribution. Advanced Optics Electronics Inc. currently owns 22.8 percent of BioModa Inc. with an option, if fully exercised which allows Advanced Optics Electronics Inc. position to move to approximately 26.5 percent of BioModa Inc.